Detalhe da pesquisa
1.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691324
2.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
3.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
4.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
5.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
6.
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Pediatr Infect Dis J
; 42(1): 66-73, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36476534
7.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Hum Vaccin Immunother
; 19(2): 2233400, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438960
8.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Nat Med
; 29(1): 147-157, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36228659
9.
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
EBioMedicine
; 81: 104128, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779491
10.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192543
11.
Status of primary and secondary mental healthcare of people with severe mental illness: an epidemiological study from the UK PARTNERS2 programme.
BJPsych Open
; 7(2): e53, 2021 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583478
12.
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Lancet Gastroenterol Hepatol
; 6(2): 92-105, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308452
13.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615860
14.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Lancet HIV
; 8(8): e474-e485, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34153264
15.
Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
Health Technol Assess
; 23(1): 1-84, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30618357